IPOpulse
Back to Ticker

Natco Pharma Limited

NSE: NATCOPHARM
Healthcare Healthcare
₹800.85
+2.01%EOD · 19 Oct

Natco Pharma Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹14,736 Cr
52W Range
₹1227 / ₹779
Volume
768K
26.9% delivery
1Y Return
-5.3%
P/E Ratio
12.4
P/B Ratio
1.5
ROE
16.9%
Debt / Equity
7.74

Peers in Healthcare

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
Natco Pharma Limited(this stock)₹800.85₹14,736 Cr12.41.516.9%0.76%
Divi's Laboratories LimitedDIVISLAB₹9,087₹2.41 L Cr83.014.516.2%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM₹4,558.7₹1.73 L Cr72.818.417.0%0.83%
Laurus Labs LimitedLAURUSLABS₹2,069₹1.12 L Cr101.821.017.7%0.12%
Zydus Lifesciences LimitedZYDUSLIFE₹1,113.9₹1.11 L Cr25.04.218.3%0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP₹7,700₹1.11 L Cr54.312.021.5%0.25%
Aurobindo Pharma LimitedAUROPHARMA₹1,621.4₹93,292 Cr26.12.69.9%0.00%
Mankind Pharma LimitedMANKIND₹2,253.2₹93,067 Cr46.05.812.4%0.00%
Max Healthcare Institute LimitedMAXHEALTH₹830₹80,785 Cr56.77.714.3%0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice
C
52/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityAverage · 53
ValuationStrong · 83
MomentumPoor · 20
High debt load (D/E 7.7)
In confirmed downtrend (Stage 4)
Inexpensive valuation (P/E 12x)

Technical Indicators

Full analysis · objective math, not advice
Returns
1D
+2.0%
1W
+0.0%
1M
-2.1%
3M
-15.8%
6M
-28.5%
1Y
-5.3%
Weinstein Stage
Stage 4 — Declining (downtrend)
RSI (14)
38 Neutral
Trend Template
1/7weak
RS vs Nifty (3M)
-12.2pp
Moving Averages (price vs MA)
20-DMA
₹813
below
50-DMA
₹842
below
150-DMA
₹949
below
200-DMA
₹934
below
From 52W High
-34.7%
From 52W Low
+2.8%
Support (20D)
₹779
Resistance (20D)
₹858

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.